Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
See below for the Latest Gilead Sciences News, Analysis, Profit Results, Share Price Information, and Commentary.
Data privacy amongst obstacles for using telehealth on HIV treatment in APAC
Almost half of people living with HIV are concerned about cybersecurity.
Data privacy amongst obstacles for using telehealth on HIV treatment in APAC
Almost half of people living with HIV are concerned about cybersecurity.
Using offline and online channels to counter misperceptions of hepatitis B – a ‘silent disease’ – in Singapore
Gilead Sciences’ US$1m grant will help NFDD and other community-based organisations across Asia battle public apathy towards liver disease.
Gilead Sciences names its new health leader for Asia markets
Dustin Haines has 20 years leadership in pharmaceuticals.
Me & My Healthcare Provider targets HIV’s ‘Achilles heel’
The International AIDS Society and Gilead Sciences partner to promote stigma-free HIV care in Asia.
Most Read
1. SGH and NNI study reveals connection between scoliosis and brainstem 2. Why rare disease policies are critical to ensure equitable access to treatment for rare disease communities in Southeast Asia 3. 3 in 5 novice nurses struggle with higher-complexity procedures 4. Synpaxe, tech giants foster GenAI in healthcare 5. EGH Campus in Bedok North to offer services before 2030 completionResource Center
Read Here
Advertise
Sign Up
Event News
Event News
Discover cutting-edge strategies reshaping healthcare delivery with EY’s Abhay Bangi
![Discover cutting-edge strategies reshaping healthcare delivery with EY’s Abhay Bangi]()
Co-Written / Partner
Explore the complexities of the healthcare landscape, as well as innovation and transformation within the sector, guided by the EY expert’s visionary insights.
Explore the complexities of the healthcare landscape, as well as innovation and transformation within the sector, guided by the EY expert’s visionary insights.
